Press release
Neurological Biomarkers Market: Pipeline Overview 2017 - 2025
The University of British Columbia and the Karolinska Institute in Sweden have set up biobanks that provide necessary resources and information for biomedical research. Alzheimer’s is the most common form of dementia affecting 12 million people. Neuroimaging and neuropsychological probes can help predict Alzheimer before behavioral tests diagnose. Thus pre-assessment tests such as Positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) are driving the demand for neurological biomarkers.
View Report Preview @ https://www.persistencemarketresearch.com/market-research/neurological-biomarkers-market.asp
The introduction of newer neurological biomarkers is expected to play a crucial role in helping neuropathologists in the characterization and selection of suitable treatment strategies. Moreover, with the advent of telehealth and personalized medicine, there is an emerging trend of single-cell biosensors as it may help integrating large-scale clinical and molecular information.
These biomarkers are used in patients suffering from acute ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage and traumatic brain injury. Recovery from such neurocritical disease depends on how well the patient mitigates. In such situations, procurement of imaging studies or a good examination may be delayed due to the complexities involved. This shortcoming has further fueled the demand for biomarkers. The market is also experiencing recent trends with the researches undertaken on novel radiotracers, miRNA, and integration of systems biology into routine biomarker validation.
The neurological market is expected to witness growth owing to the various technological developments, the expansion in application and rise in the incidence of neurological disorders such as Alzheimer's, Parkinson’s and stroke. But the industry has certain restraints such as reproduction of positive trial results, the absence of pre-analytical tests and failure to investigate the efficiency of the biomarker as compared to previous one.
Furthermore, the demand for these biomarkers is expected to propel as the demand for neurological care is increasing. In America, there are around 5.4 million people diagnosed with Alzheimer’s disease. The number is expected to triple to 16 million by 2050. The demand for procedural specialties is more as compared to on procedural specialties. This statement can be justified by the fact that the Medicare payment grew by 84% for procedural specialties and only 48% for non-procedural specialties.
On the basis of imaging techniques the neurological biomarkers market can be segment as:
Transcranial magnetic stimulation (TMS)
Diffusion tensor imaging (DTI)
Conventional structural MRI (sMRI)
Functional magnetic resonance imaging (fMRI)
Positron emission tomography (PET)
On the basis of application the neurological biomarkers market can be segment as:
Proteomics based biomarkers
Genomic based biomarkers
Imaging based biomarkers
Metabolic based biomarkers
On the basis of indication the neurological biomarkers market can be segment as:
Alzheimer's disease (AD)
Multiple sclerosis (MS)
Parkinson's disease (PD)
Autism spectrum disorder (ASD)
On the basis of end-user the neurological biomarkers market can be segment as:
Hospitals
Clinics
Diagnostic and research laboratories
On the basis of services the neurological biomarkers market can be segment as:
Sample preparation
Assay development
Biomarker validation and testing
In terms of geography, the global neurological biomarkers market has been divided into five regions including North- America, Asia- Pacific and Middle-East & Africa, Latin America and Europe. North America has a major revenue share in the neurological biomarkers industry as many prominent market players are present in this region, the number of R&D projects carried out and the government funding received by academic universities to undertake research. For instance in August 2015, researchers, patients and various non-profit organizations participated in the Imaging Dementia -- Evidence for Amyloid Scanning (IDEAS) study. The USD 100 million project aims to study the utility of amyloid PET imaging to diagnose dementia, Alzheimer’s and cognitive impairment.
Request to View TOC and Sample of Research Report @ https://www.persistencemarketresearch.com/samples/16303
Asia-Pacific is the fastest growing region as the region offers huge population base, high incidence rate of neurological abnormalities, entry of new market players and huge aging population. In developing economies such as India and China, new industry players are trying to establish their market presence by developing the generic version of the biomarker, through contract research organizations. This has further helped in reducing the manufacturing cost for the company and other production related cost.
Key players in the neurological biomarkers industry are Myriad RBM, Proteome Sciences, QIAGEN, Thermo Fisher Scientific, AbaStar MDx, Acumen Pharmaceuticals, Abiant, Aepodia, Athena Diagnostics, ImmunArray, Quanterix and Cisbio Bioassays.
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
Telephone - +1-646-568-7751
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurological Biomarkers Market: Pipeline Overview 2017 - 2025 here
News-ID: 969569 • Views: …
More Releases from Persistence Market Research
Libya Baby Diapers and Wipes Market Set to Reach US$ 392.2 Mn by 2033 Says Persi …
The Libya baby diapers and wipes market is projected to expand at a 4.5% compound annual growth rate (CAGR) from 2023 to 2033, reaching an estimated value of US$ 392.2 million by 2033. The market was valued at US$ 242.9 million at the end of 2022.
Request a Sample: https://www.persistencemarketresearch.com/samples/33030
Key Market Drivers
Several factors are underpinning the growth in the Libyan market for baby diapers and wipes:
• Growing awareness of infant hygiene: As…
Foodservice Packaging Market Worth 522.4 Billion by 2032 - Persistence Market Re …
The foodservice packaging market is undergoing significant transformation, driven by evolving consumer preferences, technological innovations, and rising sustainability demands. Foodservice packaging encompasses a wide range of products including containers, trays, cups, lids, bags, and cutlery used across quick-service restaurants, full-service dining, catering, and delivery platforms.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/22354
As global food consumption habits shift toward convenience and on-the-go…
BOPP for Labels Market to Reach US$ 31.2 Billion by 2032 with 6.1% CAGR, Reports …
The packaging and labelling industry has witnessed significant transformation over the past decade, with brands increasingly seeking materials that are cost-effective, durable, and visually appealing. One material that has gained substantial traction in this context is biaxially oriented polypropylene, commonly known as BOPP. BOPP films are widely recognized for their versatility, excellent printability, and resilience against moisture and chemicals. These characteristics make BOPP an ideal choice for labels across various…
Emulsion Explosives Market to Grow from US$ 2.57 Billion in 2024 to US$ 3.57 Bil …
The global emulsion explosive market has witnessed substantial growth over the past few years, driven by increasing demand from the mining, construction, and infrastructure sectors. Emulsion explosives are considered a safer, more efficient alternative to traditional blasting agents due to their improved performance, water resistance, and enhanced safety profile. Their adoption is growing steadily as industries seek higher productivity, better control, and environmentally safer solutions for blasting operations.
Get a Sample…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
